An investigation into Ireland's peptide gray market has delivered one of the clearest quality data points yet: independent laboratory testing found significant impurities in three of four peptide products purchased from suppliers operating in the Irish market.
The products were analyzed at Maynooth University's Department of Chemistry as part of a national current-affairs investigation.
What Happened
Investigators bought four peptide products — three from 'research only' websites and one directly from a social media content creator. Testing produced sobering results:
- Three of four samples contained significant impurities, per the principal investigator
- A Melanotan sample contained just 40% of the advertised peptide — with at least five unidentified components, the advertised peptide was a minor ingredient in its own vial
- A Retatrutide sample tested at 65% purity, versus the 98-99% expected of pharmaceutical-grade material
- All four samples contained undeclared mannitol, a harmless bulking agent that appeared on no label
- Two vials were underfilled: a 5mg vial held 2.2mg of powder; a 10mg vial held 4.8mg
None came with dosage or injection instructions, and payment required bank transfer or payment apps rather than conventional card processing.
Who Is Affected
The products belong to the 'wellness and fitness' peptide category — BPC-157, TB-500, GHK-Cu, Melanotan and similar compounds marketed with recovery, tanning and skin claims. They are neither licensed medicines nor controlled substances, leaving a regulatory gap sellers exploit with 'research only' labels.
Dublin City University research found peptides are now the second most common image and performance enhancing drugs in Ireland, behind only testosterone — and content creators are selling the substances to followers through affiliate links.
Timeline
- 2023: TB-500 seizures by Ireland's Health Products Regulatory Authority (HPRA) numbered a handful; GHK-Cu stood at five units
- 2026 year-to-date: more than 1,300 BPC-157 units seized — a 400% increase in four years — plus 200+ TB-500 units and 500+ GHK-Cu units
- October 2026: the laboratory results air, marking the first published analytical quality data on the Irish peptide gray market
What This Means for Researchers
The data give researchers a measured baseline for what 'research only' products actually contain — most strikingly the Melanotan sample, where 60% of the vial was not the advertised peptide and the components could not be identified.
The lead researcher's framing is blunt: the clinical trial is effectively happening on the population in a completely uncontrolled way. BPC-157 studies show no obvious harm and modest benefits over a couple of weeks — but there is no evidence on a year or two of use, including whether any resulting cancer might be more aggressive or harder to treat. With three of four random purchases failing basic quality expectations, purity failure is structural: unregulated manufacturing, no batch testing, no chain of custody.
How to Verify Your Peptides
Third-party laboratory testing is the only reliable way to know what a vial contains:
- Our testing lab partner program lists analytical services for purity, impurity profiles and fill quantity
- The BPC-157 testing page explains what HPLC analysis reveals about impurity profiles like those found here
- A full walkthrough of methods is in how testing works
Safe Alternatives
- Background on these compounds is in our peptides directory
- Before purchasing anything, browse our vetted vendor listings, where supplier quality signals are tracked
- For weight management, read the background on approved GLP-1 medicines rather than unapproved research compounds like Retatrutide
Sources
Independent laboratory testing at Maynooth University's Department of Chemistry; regulatory seizure statistics from Ireland's Health Products Regulatory Authority; national broadcast investigative reporting, October 2026.